YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

globe_newswire · 2026-10-20

$EG

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly develope

Sector coverage: Financial Services · Insurance - Reinsurance

Read the original at globe_newswire ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.